AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01414244 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glutamine
Description: Drug
Study NCT00742950 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal 2.8-mm corneal incision
Description: Phacoemulsification through a nasal 2.8-mm incision
Study NCT00742950 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Temporal 2.8-mm corneal incision
Description: Phacoemulsification through a 2.8-mm temporal incision
Study NCT00742950 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Superior 2.8-mm incision
Description: Phacoemulsification through a superior 2.8-mm corneal incision
Study NCT00523211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vicriviroc
Description: One tablet of vicriviroc 30 mg once daily.
Study NCT00523211 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet of placebo once daily.
Study NCT03122223 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent subtype C gp120/AS01(B)
Description: clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 20 mcg or 100 mcg, mixed with AS01B adjuvant, administered IM as a single 0.75 mL dose.
Study NCT02258672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation program
Description: Progressive and individualized physical training aimed at improving core muscles strength and endurance as well as spinal stability.
Study NCT03122223 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride for Injection, 0.9%, administered IM.
Study NCT03122223 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride for Injection, 0.9%, administered IM.
Study NCT01941433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arthritis Health Journal
Study NCT01941433 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Arthritis Health Journal
Study NCT03835351 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Urinary Catheter
Description: An intraoperative urinary catheter will be inserted which will be taken out at the end of the case
Study NCT02854787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: A bolus of 100 mcg
Study NCT02854787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: A bolus of 0,2 mcg/kg
Study NCT03644303 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT + ADT
Description: Short course SBRT to 1 or 2 oligo-progressing metastases in addition to continued abiraterone or enzalutamide
Study NCT03032432 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Elastic Garment (DEG) brace
Description: Improve function of the shoulder
Study NCT03032432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection
Description: Injection to improve rotator cuff tendinosis pain and functional score
Study NCT03032432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Description: Injection to improve rotator cuff tendinosis pain and functional score
Study NCT01034163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Study NCT01034163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02185001 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Medial Patellofemoral Ligament (MPFL) Repair
Description: The MPFL will be repaired directly at the site of the traumatic injury.
Study NCT02185001 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Patellar immobilization, stabilization, and strengthening under the direction and guidance of the physician and physical therapist.
Study NCT02755051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy for children with Chronic Insomnia and Autism Spectrum Disorder involves 8, one-hour sessions of a non-drug cognitive behavioral intervention. Session content listed below:~1. Sleep education~2. Sleep scheduling, limit setting, and stimulus control~3. Teaching relaxation strategies and other adaptive coping skills~4. Parenting strategies (differential attention, rewards, consequences)~5. Identification of maladaptive \& adaptive cognitions~6. Problem solving \& communication skills~7. Sleep restriction; bright light to change circadian rhythms~8. Review gains and plan for long-term maintenance
Study NCT00965367 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acustimulation
Description: Acupressure in P6 bilaterally given after induction of anaesthesia for 20 minutes, followed by acupressure wrist bands applied on the same acupoints for 24 hours.
Study NCT00965367 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Acustimulation
Description: Acupressure in P6 bilaterally given after induction of anaesthesia for 20 minutes, followed by acupressure wrist bands applied on the same acupoints for 24 hours.
Study NCT03343327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chronocort®
Description: Single dose of 20mg Chronocort® administered in one treatment period
Study NCT03343327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chronocort®
Description: Single dose of 20mg Chronocort® administered in one treatment period
Study NCT03343327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cortef®
Description: Single dose of 20mg Cortef® administered in one treatment period
Study NCT03343327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cortef®
Description: Single dose of 20mg Cortef® administered in one treatment period
Study NCT00291642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drops
Description: * Pharmaceutical form: Drops for oral administration~* Route of administration: Oral use
Study NCT00291642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets matching to levocetirizine
Description: * Pharmaceutical form: Tablets for oral administration~* Route of administration: Oral use
Study NCT00291642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets matching to cetirizine
Description: * Pharmaceutical form: Tablets for oral administration~* Route of administration: Oral use
Study NCT00291642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine drops
Description: * Pharmaceutical form: Drops for oral administration~* Concentration: 5 mg/ml~* Route of administration: Oral use
Study NCT00291642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine tablets
Description: * Pharmaceutical form: Tablets for oral administration~* Concentration: 5 mg~* Route of administration: Oral use
Study NCT00291642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine drops
Description: * Pharmaceutical form: Drops for oral administration~* Concentration: 10 mg/ml~* Route of administration: Oral use
Study NCT00291642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine tablets
Description: * Pharmaceutical form: Tablets for oral administration~* Concentration: 10 mg~* Route of administration: Oral use
Study NCT02802189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise programme
Description: Endurance and Resistant training exercise program (Duration: 45 minutes)~* Muscle retraining of longus colli and endurance training of the deep cervical flexors.~* Resistant exercises for the muscles involved in neck flexion, extension, side bending and rotation of the neck region. Isometric contractions exercises (20-70% of MVC) and resistant exercises (12-15RM).~* Active ROM exercises for the neck muscles~* Upper limbs exercises with resistant bands~* Stretching exercises for the neck and upper limbs muscles
Study NCT02802189 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise programme
Description: Endurance and Resistant training exercise program (Duration: 45 minutes)~* Muscle retraining of longus colli and endurance training of the deep cervical flexors.~* Resistant exercises for the muscles involved in neck flexion, extension, side bending and rotation of the neck region. Isometric contractions exercises (20-70% of MVC) and resistant exercises (12-15RM).~* Active ROM exercises for the neck muscles~* Upper limbs exercises with resistant bands~* Stretching exercises for the neck and upper limbs muscles
Study NCT02802189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Neuromuscular Inhibition Technique application.
Description: Integrated Neuromuscular Inhibition Technique application.~(Duration: 15min)~The protocol was applied to the following muscles:~* Upper border of the trapezius muscle~* sternocleidomastoid~* levator scapulae muscle~* splenius capitis muscle~Integrated Neuromuscular Inhibition Technique includes the combination of the following technique:~* Ischemic compression~* Muscle energy technique~* Strain-counterstrain technique
Study NCT01875289 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: obturator nerve block
Study NCT01684410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alpha-1 HC 200 mg
Description: Alpha-1 HC is a sterile, liquid preparation of purified alpha1-proteinase inhibitor prepared from pooled human plasma. Alpha-1 HC 200 mg inhaled once daily for 21 days for a total of 21 inhaled treatments.
Study NCT00997581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apremilast
Description: apremilast 20 mg taken twice daily by mouth
Study NCT00997581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: indomethacin SR
Description: indomethacin SR 75 mg taken twice daily by mouth
Study NCT02371525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prepmate
Description: A novel multi-modal, technology-based intervention for pre-exposure prophylaxis (PrEP) adherence support .
Study NCT01961908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex
Study NCT00032162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC 6 q4w
Study NCT00032162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: 20/30/40 mg/qm q4w Dose finding study
Study NCT03682952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprostadil Injection
Description: Participants are given alprostadil injection 10ug intravenously once a day for 2 weeks.
Study NCT03682952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beraprost sodium tablets
Description: Participants are given alprostadil injection 10ug intravenously once a day for 2 weeks ,then they take beraprost sodium tablets 40ug orally three times perday for 3 months.
Study NCT00482547 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrogel Silver Salts Coated Latex Urinary Catheter System
Description: Silver-coated catheter
Study NCT00482547 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Bard silicone elastomer coated latex catheter system
Description: Silicone-coated catheter
Study NCT02978326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-217 15/20 mg Oral Solution
Description: SAGE-217, 15 mg oral solution, BID for Days 1 to 2 followed by 20 mg oral solution BID for Days 3 to 14. If not tolerated, 15 mg for the rest of study (Days 3 to 14).
Study NCT02978326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SAGE-217 matching placebo, capsules, orally, once daily, for up to 14 days.
Study NCT02978326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE 217 30 mg Capsules
Description: SAGE-217, 30 mg, capsules, orally, once daily, for up to 14 days.
Study NCT04229849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anrotenib plus Toripalimab
Description: Anrotenib: 10 mg on day 1-14 orally repeated every 21 days; Toripalimab: 240 mg on day 1 intravenously repeated every 21 days.
Study NCT04229849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toripalimab
Description: Toripalimab: 240 mg on day 1 intravenously repeated every 21 days.
Study NCT01225146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: Ranibizumab is formulated as a sterile solution aseptically filled in a sterile 3-mL stoppered glass vial. Each vial contains 0.5 mL of 40 mg/mL (2.0-mg dose level) ranibizumab aqueous solution.
Study NCT01875289 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: obturator nerve block
Study NCT01392898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: liraglutide 1.8 mg q.d.
Study NCT01392898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: insulin dosed according titration scheme
Study NCT00617526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA806 400 mg
Study NCT00617526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT00617526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA806 1000 mg
Study NCT00617526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA806 600 mg
Study NCT00617526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA806 800 mg
Study NCT01695070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 4mg prolonged release melatonin oral tablets twice daily
Study NCT06487676 — intervention group
Intervention type: PROCEDURE
Intervention: Toe transfer
Description: Toe-to-hand transfer
Study NCT06487676 — intervention group
Intervention type: PROCEDURE
Intervention: Replantation
Description: Finger or thumb replantation after amputation
Study NCT01264224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028
Description: tablets, oral administration, single/multiple dosing, dose escalation
Study NCT03478059 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive and Motor Dual-task Intervention
Description: The intervention will take place 3 times per week for 6 weeks (60 minutes/session) and employs motor and cognitive challenges. It is based on known motor and cognitive deficits after mTBI and is structured using a theoretical framework published in another domain of neurologic disease. The intervention will consist of 6 stations that target known motor and cognitive impairments after mTBI. Each station will have 3 levels of difficulty with optional cognitive progressions. Subjects will spend 8 minutes at each station with a 2 minute transition/rest period between stations and will be progressed in motor and cognitive difficulty as able.
Study NCT03478059 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive and Motor Dual-task Intervention
Description: The intervention will take place 3 times per week for 6 weeks (60 minutes/session) and employs motor and cognitive challenges. It is based on known motor and cognitive deficits after mTBI and is structured using a theoretical framework published in another domain of neurologic disease. The intervention will consist of 6 stations that target known motor and cognitive impairments after mTBI. Each station will have 3 levels of difficulty with optional cognitive progressions. Subjects will spend 8 minutes at each station with a 2 minute transition/rest period between stations and will be progressed in motor and cognitive difficulty as able.
Study NCT01491620 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 532 nm KTP laser
Description: Laser treatment sessions on the neck and/or chest
Study NCT04360811 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: COVID 19 diagnostic test by PCR
Description: 1. Inclusion of patients with clinical data (in a eCRF) and various samples collection according to the outcome of pregnancy~2. Storage and freezing samples for subsequent analysis by RT-PCR COVID-19 (maternal saliva, cord blood, fetal stools, placenta, fetal tissue, amniotic fluid according to pregnancy outcomes) and by maternal and newborn and / or fetal serologies testing~3. Pathological study of placentas and fetal autopsies~   * Histology of positive COVID-19 placentas~  * Brain and visceral histology of positive COVID-19 fetuses autopsied~4. Analysis of patient comorbidities and comparison in the different groups~5. Final statistical analysis
Study NCT00513968 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: a mixed plasmid DNA (HB-110)
Description: HB-110 2mg (or 4mg or 8mg), im, every other week, from week 0 to week 22 (total 12 injections) and Adefovir(Adefovir dipivoxil 10mg), od, from week -10 to from week 48.
Study NCT01876459 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Study NCT03311906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.8% Hyaluronic Acid
Description: Application of 0.8% hyaluronic acid after scaling and root planing
Study NCT03311906 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and Root Planing
Description: Scaling of the teeth using hand and ultrasonic scalers followed by planing of the root with curettes
Study NCT03311906 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and Root Planing
Description: Scaling of the teeth using hand and ultrasonic scalers followed by planing of the root with curettes
Study NCT03020368 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Leeches
Study NCT03020368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Study NCT02354118 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heparinized saline catheter flush
Description: The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
Study NCT02354118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline-only catheter flush
Description: The intervention group will have their port catheters flushed with saline only.
Study NCT01331564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: electronic intervention during pregnancy and postpartum
Description: Electronically-mediated behavioral interventions to encourage women to gain an appropriate amount of weight during pregnancy and to follow a healthy lifestyle postpartum to minimize postpartum weight retention
Study NCT01331564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: electronic intervention during pregnancy
Description: Electronically-mediated behavioral interventions to encourage women to gain an appropriate amount of weight during pregnancy.
Study NCT01331564 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control women will receive non-weight related content during both time periods at the project website.
Study NCT04155801 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salix Probiotic Blend
Description: Oral capsule. The probiotic strains comprise the Salix Probiotic Blend include 3 strains of Bifidobacterium lactis (Bl-04®, Bi-07®, HN019) and 2 strains of lactobacillus (Lactobacillus acidophilus \[NCFM\]® and Lactobacillus paracasei \[Lpc-37\]®).
Study NCT01876459 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: lumbar puncture
Study NCT04583501 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab will used as dose comparable to to 0.016 mg/kg/IU in serum.
Study NCT03847402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The early integrated intervention for GDD
Description: The early integrated intervention for GDD integrates developmental approaches with strategies of applied behavior analysis.
Study NCT03847402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The early integrated intervention for ASD
Description: The theoretical underpinnings of the early integrated intervention for ASD originate from Early Start Denver Model.
Study NCT03847402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The early integrated intervention for ADHD
Description: The methods of the early integrated intervention for ADHD includes behavior training, sensory integration training and psychological counseling
Study NCT03847402 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: community intervention for ASD
Description: TEACCH (Treatment and Education of Autistic and related Communication- handicapped Children) intervention or ABA(applied behavior analysis) intervention
Study NCT03847402 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community intervention for GDD
Description: community intervention based on developmental approaches
Study NCT03847402 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: community intervention for ADHD
Description: School and family education
Study NCT03000153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Completing the Goals Form
Description: The Goals Form is a personalised outcome measure where clients enter their goals in collaboration with their assessor. Goals are then rated at the start of every session and open the therapeutic dialogue.
Study NCT05645991 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coconut Sap Powder (CSP)
Description: CSP was given once daily (1.5 g/day) for 8 weeks.
Study NCT05645991 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules containing aspartame (1.5 g/day) were taken orally once daily for 8 weeks.